Chin Lee

Dr. Chin Lee joined Connect as Chief Medical Officer in March 2022 and brings more than 15 years of clinical research and development experience in the biopharmaceutical industry across multiple therapeutic areas. Prior to Connect, Dr. Lee served as Vice President, Head of Clinical Science, and Chief Medical Officer at Theravance Biopharma, Inc. Previously, Dr. Lee was Lead Group Medical Director within the Genentech Research & Early Development (gRED) group at Genentech, Inc. Dr. Lee also held roles of increasing responsibility at Eli Lilly & Company, serving most recently as Global Senior Medical Director, Immunology Therapeutic Area, within the Bio-medicines Business Unit, and he also served as Associate Medical Director, Immunoscience Group, at Abbott. He has successfully led the submission of global regulatory filings, including for U.S. Food and Drug Administration approvals, and product commercialization across multiple autoimmune and immunology disease indications. Before entering the biopharmaceutical industry, Dr. Lee was on the academic faculty at the Northwestern University Feinberg School of Medicine in the Division of Rheumatology. Dr. Lee received a B.S. in Biology and an M.D. from the University of North Carolina at Chapel Hill and an M.P.H. from Northwestern University.